AD-2091 / Yuhan Corp - LARVOL DELTA

Efficacy and safety of low-dose antihypertensive combination drugs including amlodipine, telmisartan, and chlorthalidone: a multicenter, randomized, double-blinded, parallel, phase III clinical trial (ESC-WCC 2025) - "In conclusion, this study suggests that AD-209, a low-dose combination of telmisartan (20 mg), amlodipine (2.5 mg), and chlorthalidone (6.25 mg) provides a significant blood pressure-lowering effect compared to telmisartan (40 mg), in patients with essential hypertension, with a similar safety profile."

Clinical • P3 data • Cardiovascular • Hypertension

Phase III Study to Evaluate the Efficacy and Safety of AD-209 (clinicaltrials.gov) - P3 | N=280 | Recruiting | Sponsor: Addpharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension